XenoPort News

In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc.

GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 FDA Review Date to February 9, 2010 Submitted by admin on 11/6/2009 @ 6:15 PM Companies mentioned in this article: XenoPort, Inc.

Xtremepicks.com Alerts include Taylor Capital Group, Inc. , Starbucks Coffee Company , XenoPort, Inc.

XenoPort, Inc. announced today that it will release its third quarter financial results on November 3, 2009 at approximately 4:00 p.m. Eastern Time.

XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil , also known as XP19986, in patients with gastroesophageal reflux disease who remain symptomatic despite treatment with a proton pump inhibitor .

Depomed Inc. on Monday reported a successful late stage clinical trial of a drug intended to treat pain following the viral infection shingles, and its shares soared on the news.

Positive Phase IIb Results for GSK1838262 Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.-- --Sep 17, 2009 - GlaxoSmithKline and XenoPort, Inc.

GlaxoSmithKline and XenoPort announced clinical trial data yesterday on their drug to treat nerve pain following shingles, and the news was anything but painful .

Main Category: Pain / Anesthetics Also Included In: Neurology / Neuroscience GlaxoSmithKline and XenoPort, Inc.

Biopharmaceutical company XenoPort Inc and its partner GlaxoSmithKline Plc said their neuropathic pain drug met the main goal of reducing the intensity of pain in a mid-stage trial.

Investors where fired up Thursday after XenoPort Inc. reported top-line Phase IIb results showing that its gabapentin prodrug significantly reduced neuropathic pain associated with post-herpetic neuralgia in adults, driving shares up 25.6 percent.

GlaxoSmithKline and Xenoport Inc. said Thursday their developing neuropathic pain treatment candidate met its key goal of lowering pain intensity in a midstage study.

Sep 8, 2009 - XenoPort, Inc. announced today preliminary results from a Phase 2 clinical trial that evaluated the safety and tolerability of arbaclofen placarbil , also known as XP19986, when administered without titration to patients with acute back spasms.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Reissuing release to correct ticker symbol for searching purposes. The release reads: XenoPort, Inc.

XenoPort, Inc. August 5, 2009 5:00 pm ET Executives Jackie Cossmon a ' IR Ron Barrett a ' CEO Bill Harris a ' SVP, Finance and CFO Bill Rieflin a ' President Analysts Eric Schmidt a ' Cowen and Company Lucy Lu a ' Citi Presentation Operator Good afternoon.

XenoPort, Inc. August 5, 2009 5:00 pm ET Executives Jackie Cossmon a ' IR Ron Barrett a ' CEO Bill Harris a ' SVP, Finance and CFO Bill Rieflin a ' President Analysts Eric Schmidt a ' Cowen and Company Lucy Lu a ' Citi Presentation Operator Good afternoon.

XenoPort, Inc. August 5, 2009 5:00 pm ET Executives Jackie Cossmon a ' IR Ron Barrett a ' CEO Bill Harris a ' SVP, Finance and CFO Bill Rieflin a ' President Analysts Eric Schmidt a ' Cowen and Company Lucy Lu a ' Citi Presentation Operator Good afternoon.

The evidence of efficacy for the NDA filing will be based on data from Astellas' successful Phase 2 study in RLS patients conducted in Japan and XenoPort's clinical program conducted in the United States.

With hundreds of items on the - SANTA CLARA, Calif.-- --XenoPort, Inc. announced today that it will release its second quarter financial results on August 5, 2009 at approximately 4:30 p.m. Eastern Time.